HCPCS Code J3487: Deleted code, crosswalk to J3489, and billing guide

Key takeaways

HCPCS Code J3487 (injection, zoledronic acid / Zometa, 1 mg) is a deleted code and cannot be used on current Medicare or commercial insurance claims.

The active successor is J3489, billed per 1 mg of zoledronic acid administered. Units on the claim must match the dose given.

Oncology bills 4 units for a 4 mg Zometa dose, while rheumatology bills 5 units for a 5 mg Reclast infusion.

Medicare covers zoledronic acid for five indications under LCD L33270: hypercalcemia of malignancy, bone metastases, multiple myeloma, osteoporosis, and Paget disease of bone.

Practice management software like Pabau helps infusion practices track drug units, attach ICD-10 codes, and submit clean zoledronic acid claims.

HCPCS Code J3487 is a deleted Level II code that described injection of zoledronic acid (Zometa), 1 mg. J3489 replaced it, and J3489 is the only code Medicare and commercial payers now accept for this drug.

The old code still turns up in charge masters, EHR order sets, and inherited superbills.

Below you will find the deletion history, the crosswalk to J3489, and every Medicare-covered indication. The rest covers the required ICD-10-CM codes, reimbursement, documentation, and the errors that trigger denials.

HCPCS Code J3487: Description, status, and quick reference

HCPCS Code J3487 was a Level II Healthcare Common Procedure Coding System code describing injection of zoledronic acid (Zometa), 1 mg.

It sat in the HCPCS Level II system maintained by the Centers for Medicare and Medicaid Services (CMS). That system covers drugs, biologicals, and non-physician services billed to Medicare Part B and most commercial payers.

The code is now deleted. Any claim submitted today with J3487 as the drug code will be rejected by Medicare and most commercial payers. The table below summarizes the core code facts.

Code status and deletion history

J3487 was deleted by CMS as part of a routine HCPCS Level II annual update. CMS consolidates or revises drug codes when a descriptor no longer reflects current billing conventions. It also does so when a new code gives more precise coverage.

Practices working from billing templates built before the deletion date are the usual source of continued J3487 use. The AAPC HCPCS code database lists J3487 as deleted, with J3489 as the crosswalk replacement.

Submitting a deleted HCPCS code does not simply reduce the payment. The claim is rejected outright, so nothing is paid until you correct and resubmit it. For practices running zoledronic acid on a schedule, such as annual osteoporosis infusions, repeated rejections tie up cash for weeks.

Understanding medical billing fundamentals helps billing teams audit their charge masters for deleted codes before claims go out, not after.

Crosswalk: HCPCS Code J3487 replaced by J3489

J3489 is the active replacement for J3487. Both codes describe injection of zoledronic acid at 1 mg per billing unit. J3489 is the one Medicare and commercial payers accept today. The table below compares them side by side.

One distinction matters for billing teams. J3487’s descriptor named Zometa by brand. J3489 uses a generic descriptor, so it covers Zometa for oncology dosing and Reclast for the annual 5 mg osteoporosis infusion. Practices administering either brand now use J3489.

Covered clinical indications under LCD L33270

Medicare covers zoledronic acid infusions under LCD L33270, Bisphosphonates (Intravenous [IV]) and Monoclonal Antibodies in the Treatment of Osteoporosis and Their Other Indications.

Coverage is limited to medically necessary indications. Off-label use may need prior authorization and is not automatically covered under this LCD. The five covered indications and their ICD-10-CM codes are listed below.

Verify ICD-10-CM codes against the current year’s CMS update file before you submit. Codes are revised annually, and an outdated code is a common source of denials.

ICD-10-CM codes you must link to the claim

Every zoledronic acid claim needs a linked ICD-10-CM diagnosis code that matches a covered LCD indication. A missing or mislinked diagnosis code is one of the leading causes of denial on infusion drug claims. Several secondary codes commonly appear on the same claim.

• Bone metastases claims: always link the primary malignancy code, such as C34.x for lung cancer, alongside C79.51 or C79.52. Medicare expects both codes on the claim.
• Multiple myeloma claims: specify the disease stage with the fifth digit. C90.00 is not in remission, C90.01 is in remission, and C90.02 is in relapse. Stage-unspecified submissions invite audits.
• Osteoporosis claims: for annual Reclast infusions, document the bone density (DXA) T-score in the medical record. Use M81.0 for age-related osteoporosis without a current pathological fracture, or M80.00XA when an acute fracture is the trigger.
• Hypercalcemia of malignancy: E83.52 goes in as the primary code, and the underlying malignancy code follows as a secondary.

The CMS fee schedule lookup lets billers check which ICD-10-CM codes a drug code accepts and confirm coverage before submission.

Medicare reimbursement for zoledronic acid infusion

Medicare Part B reimburses zoledronic acid under J3489 using the Average Sales Price (ASP) methodology. CMS sets payment at ASP plus 6% for physician office settings. Hospital outpatient departments bill under the Outpatient Prospective Payment System (OPPS), which calculates payment differently.

Site of service drives that difference, so how your revenue cycle management process captures it matters. A physician office claim and a hospital outpatient claim for the same drug are processed on different rules.

ASP-based rates change quarterly. CMS publishes an updated ASP drug pricing file each quarter, so the zoledronic acid rate in January will differ from the rate in October. Check the current CMS file before you quote patients or project drug revenue.

Site-of-service billing rule: practices administering the infusion in a physician office use Place of Service code 11 and bill J3489 on a CMS-1500. Hospital outpatient infusion suites bill on a UB-04 with the applicable revenue code. The payment difference between the two settings can be significant for high-dose oncology regimens.

Documentation the medical record must contain

LCD L33270 sets out what the record must contain to support a zoledronic acid claim. Miss any required element and the payer has grounds for denial or recoupment on audit. Structured IV therapy intake forms and pre-infusion checklists catch missing detail before the patient reaches the chair.

• Diagnosis and medical necessity: the chart must state the covered indication. Support it with lab values such as serum calcium, imaging such as a bone scan or PET, or pathology from a biopsy.
• Infusion start and stop times: document the exact time the infusion began and ended. This supports the drug code and any administration CPT codes billed alongside it.
• Drug dose administered: record the exact milligrams infused. Units on the HCPCS claim must match the documented dose, so a 4 mg Zometa dose needs 4 units of J3489.
• Ordering physician: the name and NPI of the ordering clinician must appear in the record. For oncology infusions, the treating oncologist’s order belongs in the chart at the time of infusion.
• Prior authorization status: where the payer requires it, and commercial insurers often do, record the authorization number in the chart and the claim notes. PA requirements vary by payer and change annually.
• Relevant lab or imaging results: DXA T-score for osteoporosis, alkaline phosphatase for Paget disease, and calcium levels for hypercalcemia. Without these, medical necessity is hard to defend on audit.

Consistent documentation templates cut the time staff spend preparing records for pre-payment reviews and post-payment audits. They also remove the variability that creates compliance risk. Good medical billing compliance begins in the clinical note, well before anyone opens the claim form.

Billing guidelines and step-by-step coding workflow

Practices billing zoledronic acid today should run the same workflow on every encounter. Claims management software that validates drug codes against active HCPCS tables catches deleted-code errors before the claim leaves the practice.

1. Confirm you are using J3489, not J3487. Remove J3487 from every charge master, superbill, and EHR order set. J3487 is deleted and will be rejected.
2. Calculate units based on the dose administered. J3489 is billed per 1 mg. A 4 mg Zometa infusion is 4 units. A 5 mg Reclast infusion is 5 units.
3. Select the correct ICD-10-CM code. Match the diagnosis code to the LCD-covered indication. For bone metastases, include both the secondary-site code and the primary malignancy code.
4. Bill the administration CPT code alongside J3489. Intravenous infusion administration is reported separately with 96365 for the initial infusion, up to one hour, and 96366 for each additional hour. An IV push uses 96374 instead, so match the code to what the record documents.
5. Attach required documentation. Confirm the chart contains every element LCD L33270 requires before submission. A clean claim with complete documentation is less likely to be pulled for review.
6. Check prior authorization status. For commercial payers, verify PA was obtained before the infusion. The PA number goes in Box 23 of the CMS-1500 form.
7. Submit and track the claim. Watch for rejection or denial inside the payer’s processing window. Flag the claim for follow-up if nothing comes back within 30 days.

A superbill that pre-populates J3489 with the right administration CPT code cuts manual entry errors and speeds up recurring infusion appointments.

Common coding errors and how to correct them

Zoledronic acid claims fail for a predictable set of reasons, and most are correctable with a focused pre-claim audit. Strong denial management means knowing which error produces which denial code, so the billing team can fix them systematically.

Submitting a clean claim for zoledronic acid means getting all six elements right at once. One missing piece creates a denial that costs more to fix than it would have cost to prevent.

Specialty considerations: Oncology and rheumatology practices

Zoledronic acid is given in specialty settings that bill it very differently. The dose, the claim form, and the prior authorization pattern all shift with the setting, as the comparison below shows.

Oncology practices typically administer zoledronic acid in a dedicated infusion suite. The facility and professional components are often split. The facility bills the drug and administration under OPPS on a UB-04, and the oncologist bills separately for evaluation and management.

On multi-drug encounters, J3489 sits alongside the chemotherapy codes and supportive-care drugs such as J3250, with the 96365 series covering administration time. Oncology practices need IV therapy EMR software that handles split billing, concurrent infusion tracking, and drug unit documentation in one workflow.

Rheumatology practices more often give the drug as the annual osteoporosis infusion, Reclast at 5 mg. These encounters are usually billed entirely by the physician practice on a CMS-1500. The practice bills J3489 at 5 units plus the administration code.

The office visit E/M is added when a separate evaluation happens that day. Modifier -25 belongs on that E/M code to show a separately identifiable service. The same modifier question comes up when the practice also bills 20611 for an image-guided joint injection.

Prior authorization patterns by specialty: commercial payers frequently require PA for oncology uses such as bone metastases and multiple myeloma. They apply different rules to osteoporosis infusions.

Practices billing annual Reclast infusions find PA rules differ between Blue Cross plans, UnitedHealth, and regional payers. The same is true for other rheumatology drug codes such as J1438, so verify with each payer at the start of the plan year.

IV infusion practice software that ties prior authorization tracking to the scheduling workflow stops an infusion going ahead before PA is confirmed.

Related HCPCS codes for intravenous bisphosphonates

Billers working on these claims will meet the codes below. Knowing when each one applies prevents inappropriate substitution and keeps claims from being denied for a code mismatch.

The PGM Billing HCPCS lookup searches current HCPCS Level II codes from CMS source data and confirms whether a drug code is active or deleted.

How claims management software keeps J3489 claims clean

Most infusion practices find a deleted drug code the same way. The rejection comes back, someone opens the charge master, and the claim goes out again two weeks later. The code was already wrong before the patient sat down.

Practice management software like Pabau works the other way around. The drug code, the units, and the ICD-10-CM diagnosis are captured in the treatment note, then carried onto the claim. Submission runs through our Claim.MD integration, so rejections land back in the record your team already works in.

That matters most for practices running infusions on a schedule. Oncology suites, rheumatology offices, and the functional medicine practices that run their own infusion rooms all document differently. One pre-claim check, built once, covers every setting you bill from.

Send infusion claims out right the first time

Pabau’s claims management tools validate HCPCS codes, attach the ICD-10 diagnosis, and track submission status. Your zoledronic acid claims go out right the first time.

Book a demo

Conclusion

J3487 is not a problem you can fix at the claim level. Pull it out of the charge master, the superbills, and the EHR order sets, and the rejections stop at the source.

After the swap, what remains is arithmetic and linkage. Units must equal milligrams given, and the diagnosis must match a covered LCD indication. The chart also has to carry infusion times and medical necessity. Those three checks prevent most of the denials this drug generates.

The trade-off worth remembering is timing. ASP rates move every quarter and PA rules move every plan year, so a workflow that was clean in January can start failing by October. Book a demo to see how Pabau keeps drug codes, units, and diagnoses aligned for oncology and rheumatology billing.

Continue your research

Opening an infusion practice? How to open an IV therapy clinic walks through licensing, staffing, and the billing setup you need on day one.

Billing another drug code CMS retired? HCPCS Code J3365 sets out what to bill in its place.

Treating oncology and rheumatology patients in one suite? HCPCS Code J9312 covers rituximab billing units and modifiers.

Coding osteoporosis without a fracture? ICD-10 Code M81.8 explains when the other-osteoporosis code applies.

Building the care plan behind the annual infusion? Osteoporosis care plan template gives you a structure to document it.

Frequently asked questions